Overview

Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studied the side effects and best dose of clofarabine when given together with cytarabine and to see how well they work in treating older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have relapsed or not responded to treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Collaborator:
National Cancer Institute (NCI)
Treatments:
Clofarabine
Cytarabine